Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025, alleging that the company misled investors regarding the efficacy of its drug candidate, Efzofitimod [1][2]. Allegations - The lawsuit claims that aTyr Pharma provided misleading information about the Phase 3 study of Efzofitimod, which was designed to evaluate its safety and efficacy in patients with pulmonary sarcoidosis. The company's executives expressed confidence in the study's design while allegedly concealing the drug's inability to allow patients to taper off steroids completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48. Following this announcement, the stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Next Steps - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by December 8, 2025. Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4]. About Robbins LLP - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sina Corporation, Inc., (“Sina” or the "Company") (NASDAQ: SINA) investors off a class action on behalf of investors that bought securities between October 13, 2020 and March 22, 2021, inclusive (the “Class Period”). Sina investors have until November 18, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of investors that bought securities between March 29, 2024 and June 27, 2025, inclusive (the “Class Period”). Unicycive investors have until October 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to dis ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cepton, Inc., (“Cepton” or the "Company") (NASDAQ: CPTN) investors of a class action on behalf of investors that bought securities between July 29, 2024 and January 6, 2025, inclusive (the “Class Period”). Cepton investors have until December 8, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises C3.ai, Inc., (“C3” or the "Company") (NASDAQ: AI) investors of a class action on behalf of investors that bought securities between February 26, 2025 and August 8, 2025, inclusive (the “Class Period”). C3 investors have until October 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join th ...

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-8903 SOURCE The Gross Law Firm ALLEGATIONS: The complain ...

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Snap Inc. (NYSE: SNAP). Shareholders who purchased shares of SNAP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SNAP during the timeframe listed above, you will be enrolled in a portfolio monitoring ...

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth and the impact of its CEO's health on the company's performance, leading to a significant drop in stock price following disappointing financial results [1][2]. Summary by Sections Allegations - The complaint claims that C3.ai's management made overly positive statements while concealing material adverse facts about the company's growth, particularly regarding the CEO's health affecting deal closures and overall performance [1]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [1]. Stock Price Impact - Following the announcement of poor financial results, C3.ai's stock price fell from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [1]. Class Action Details - Shareholders who purchased shares during the specified class period (February 26, 2025, to August 8, 2025) are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 21, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, aiming to ensure companies adhere to responsible business practices [3].